Novel thiosemicarbazide hybrids with amino acids and peptides against hepatocellular carcinoma: A molecular designing approach towards multikinase inhibitor

Current Computer-Aided Drug Design

Volumn 11, Issue 3, 2015, Pages 279-290

  Chacko, Shinu ^a   Samanta, Subir ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

ADMET; Checkpoint kinase 1; Glide 5.0; Hepatocellular carcinoma; LD50; Peptide; Thiosemicarbazide; VEGFR 2

Indexed keywords

AMINO ACIDS; BIOACTIVITY; CRYSTAL STRUCTURE; DIAGNOSIS; ENZYMES; MOLECULAR MODELING; TOXICITY;

ADMET; AMINO-ACIDS; BIOLOGICAL SCREENING; CHECKPOINT KINASE-1; GLIDE 5.0; HEPATOCELLULAR CARCINOMA; IN-VITRO; LD50; THIOSEMICARBAZIDES; VEGFR-2;

PEPTIDES;

CHECKPOINT KINASE 1; SORAFENIB; THIOSEMICARBAZIDE; VASCULOTROPIN RECEPTOR 2; AMINO ACID; PEPTIDE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; SEMICARBAZIDE DERIVATIVE;

ADAPTATION; ARTICLE; CELL MEMBRANE PERMEABILITY; CRYSTAL STRUCTURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; HYDROGEN BOND; LD50; LIPOPHILICITY; LIVER CELL CARCINOMA; MOLECULAR BIOLOGY; MOLECULAR DOCKING; MOLECULAR WEIGHT; THREE DIMENSIONAL IMAGING; VALIDATION PROCESS; X RAY CRYSTALLOGRAPHY; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM;

AMINO ACIDS; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; PEPTIDES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SEMICARBAZIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84959451374     PISSN: 15734099     EISSN: 18756697     Source Type: Journal    
DOI: 10.2174/1573409911666151103114300     Document Type: Article

References (37)

1. Alisi, A.; Balsano, C. Enhancing the efficacy of hepatocellular carcinoma chemotherapeutics with natural anticancer agents. Nutr. Rev. 2007, 65(12), 550-553.
2. Velázquez, R. F.; Rodriguez, M.; Navascues, C. A.; Linares, A.; Perez, R.; Sotorríos, N. G.; Martinez, I.; Rodrigo, L. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003, 37(3), 520-527.
3. Lo, A.; Lin, C.T.; Wu, H.C. Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol. Cancer. Ther. 2008, 7(3), 579-589.
4. Farazi, P.A.; DePinho, R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6(9), 674-687.
5. Wisnom, C.; Siegel, M.A. Advances in the diagnosis and management of human viral hepatitis. Dent. Clin. North. Am. 2003, 47(3), 431-447.
6. Persidis, A. Cancer multidrug resistance. Nat. Biotechnol. 2000, 17(1), 94-95.
7. Li, C. Poly (L-glutamic acid)–anticancer drug conjugates. Adv. Drug. Deliv. Rev. 2002, 54(5), 695-713.
8. Evindar, G.; Batey, R.A. Peptide heterocycle conjugates: a diverted edman degradation protocol for the synthesis of N-terminal 2- Iminohydantoins. Org. Lett. 2003, 5(8), 1201-1204.
9. Bauer, D.; Sadler, P. The structure-activity relashionship of the antiviral chemotherapeutic activity of Isatin β-thiosemicarbazone. Brit. J. Pharm. Chemoth. 1960, 15(1), 101-110.
10. Zhang, H.-J.; Qian, Y.; Zhu, D.-D.; Yang, X.-G.; Zhu, H.-L. Synthesis, molecular modeling and biological evaluation of chalcone thiosemicarbazide derivatives as novel anticancer agents. Eur. J. Med. Chem. 2011, 46(9), 4702-4708.
11. Barry, V.C.; Conalty, M.; O'Callaghan, C.; Twomey, D. In: Anticancer agents: III synthesis and anticancer activity of some bisthiosemicarbazones and thiosemicarbazides, Proceedings of the Royal Irish Academy. Section B: Biological, geological, and chemical science, JSTOR: 1966, pp. 309-324.
12. Joseph-McCarthy, D. Computational approaches to structure-based ligand design. Pharmacol. Ther. 1999, 84(2), 179-191.
13. Morris, G. M.; Lim-Wilby, M. Molecular docking. Methods. Mol. Biol. 2008, 443, 365-382.
14. Llovet, J.M.; Bruix, J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol. 2008, 48(Suppl 1), S20-37.
15. Tanaka, S.; Arii, S. Molecular targeted therapies in hepatocellular carcinoma. Semin. Oncol. 2012, 39(4), 486-492.
16. Zhang, L.; Wang, X.; Feng, J.; Jia, Y.; Xu, F.; Xu, W. Discovery of novel vascular endothelial growth factor receptor 2 inhibitors: a virtual screening approach. Chem. Biol. Drug. Des. 2012, 80(6), 893-901.
17. Kumar, V.; Khan, S.; Gupta, P.; Rastogi, N.; Mishra, D.P.; Ahmed, S.; Siddiqi, M.I. Identification of novel inhibitors of human Chk1 using pharmacophore-based virtual screening and their evaluation as potential anti-cancer agents. J. Comput. Aided. Mol. Des. 2014, 28(12), 1247-1256.
18. Xie, Y.; Wei, R.-R.; Huang, G.-L.; Zhang, M.-Y.; Yuan, Y.-F.; Wang, H.-Y. Checkpoint kinase 1 is negatively regulated by miR- 497 in hepatocellular carcinoma. Med. Oncol. 2014, 31(3), 1-5.
19. Garrett, M.D.; Collins, I. Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol. Sci. 2011, 32(5), 308-316.
20. Li, J.; Tan, H.; Dong, X.; Xu, Z.; Shi, C.; Han, X.; Jiang, H.; Krissansen, G.W.; Sun, X. Antisense integrin alphaV and beta3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas. Dig. Liver Dis. 2007, 39(6), 557-565.
21. Patrick, G. L. An introduction to medicinal chemistry. 4th ed.; Oxford University Press Inc.: New York, 2009, p 772.
22. Lipinski, C.A. Lead-and drug-like compounds: the rule-of-five revolution. Drug Discov. Today Technol. 2004, 1(4), 337-341.
23. Cheung, W.S.; Calvo, R.R.; Tounge, B.A.; Zhang, S.-P.; Stone, D.R.; Brandt, M.R.; Hutchinson, T.; Flores, C.M.; Player, M.R. Discovery of piperidine carboxamide TRPV1 antagonists. Bioorg. Med. Chem. Lett. 2008, 18(16), 4569-4572.
24. Drwal, M.N.; Banerjee, P.; Dunkel, M.; Wettig, M.R.; Preissner, R. ProTox: a web server for the in silico prediction of rodent oral toxicity. Nucleic Acid Res. 2014, 42(Web Server issue), W53-W58.
25. RCSB Proteine Data Bank Co-crystal structure of Checkpoint Kinase Chk1 with a pyrrolo-pyridine inhibitor. http://www.rcsb.org/pdb/explore/explore.do?structureId=1zys (Accessed March 12, 2014).
26. Patil, V.; Gupta, S.; Samanta, S.; Masand, N. Virtual screening of imidazole analogs as potential hepatitis C virus NS5B polymerase inhibitors. Chem. Pap. 2013, 67(2), 236-244.
27. Ganguly S. Murugesan, Docking studies of novel tetrahydroquinoline and tetrahydroisoquinoline analogues into the non-nucleoside inhibitor binding site of HIV-1 RT. Rasayan J. Chem. 2008, 1(2), 251-257.
28. Repasky, M.P.; Shelley, M.; Friesner, R.A. Flexible ligand docking with Glide. Curr. Protoc. Bioinformatics 2007, Chapter 8, Unit 8.12. doi: 10.1002/0471250953.bi0812s18.
29. Kunda, P.K.; Rao, J.V.; Mukkanti, K.; Induri, M.; Reddy, G.D. Synthesis, anticonvulsant activity and in silco studies of schiff bases of 2-aminothiophenes via guanidine- catalyzed gewald reaction. Trop. J. Pharm. Res. 2013, 12(4), 566-576.
30. Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47(7), 1739-1749.
31. Foye, W.O.; Lemke, T.L.; Williams, D.A. Foye's principles of medicinal chemistry. 6th ed.; Lippincott Williams & Wilkins: 2008.
32. Di, L. Strategic approaches to optimizing peptide ADME properties. AAPS J., 2015, 17(1), 134-143.
33. Radi, M.; Dreassi, E.; Brullo, C.; Crespan, E.; Tintori, C.; Bernardo, V.; Valoti, M.; Zamperini, C.; Daigl, H.; Musumeci, F.; Carraro, F.; Naldini, A.; Filippi, I.; Maga, G.; Schenone, S.; Botta, M. Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study. J. Med. Chem. 2011, 54(8) 2610- 2626.
34. Segall, M.D.; Barber, C. Addressing toxicity risk when designing and selecting compounds in early drug discovery. Drug Discov. Today 2014, 19(5), 688-693.
35. PROTOX Prediction of rodent oral toxicity. http://tox.charite.de/tox/ (Accessed Jan 26, 2015).
36. UN, Globally Harmonized System of Classification and Labelling of Chemicals (GHS). In UN GHS website, Fourth Revised Edition ed.; United Nations: 2005.
37. Murcko, M.A. Computational methods to predict binding free energy in ligand-receptor complexes. J. Med. Chem. 1995, 38(26), 4953-4967.